This CD19-4D5-fused scFv molecule potentiates CD19 CAR T cells to target ErbB2+ cancer cells and repress tumor development by displaying a 100-fold greater selectivity toward cancerous cells than healthy fibroblasts, which was not seen in ErbB2 CAR T cells alone (without scFv fusion). This evidence concerns the gene ERBB2 and neoplasm.